[
  {
    "ts": null,
    "headline": "IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries",
    "summary": "Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.",
    "url": "https://finnhub.io/api/news?id=bd685a46948d95e5db7557374c160e599626eb18b4080f0bf21d17b8a9ba55c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745526380,
      "headline": "IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries",
      "id": 134067644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.",
      "url": "https://finnhub.io/api/news?id=bd685a46948d95e5db7557374c160e599626eb18b4080f0bf21d17b8a9ba55c0"
    }
  },
  {
    "ts": null,
    "headline": "Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints",
    "summary": "Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in patients with persistent atrial fibrillation (AF). Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in Circulation.",
    "url": "https://finnhub.io/api/news?id=c8df38b477defa1d61d5ba1c73352f4729fb4c68effcda4485a8210529d0d5a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745523660,
      "headline": "Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints",
      "id": 134067645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in patients with persistent atrial fibrillation (AF). Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in Circulation.",
      "url": "https://finnhub.io/api/news?id=c8df38b477defa1d61d5ba1c73352f4729fb4c68effcda4485a8210529d0d5a5"
    }
  },
  {
    "ts": null,
    "headline": "BSX Q1 Earnings Call: Outperformance Driven by Cardiology and Electrophysiology, Guidance Raised Amid Tariff Headwinds",
    "summary": "Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. The company expects next quarter’s revenue to be around $4.88 billion, close to analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=3b7d02e048294d052032c78fe603af5976f4fab9f3bbfba554135ea4a4ca983b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745522704,
      "headline": "BSX Q1 Earnings Call: Outperformance Driven by Cardiology and Electrophysiology, Guidance Raised Amid Tariff Headwinds",
      "id": 134067646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. The company expects next quarter’s revenue to be around $4.88 billion, close to analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=3b7d02e048294d052032c78fe603af5976f4fab9f3bbfba554135ea4a4ca983b"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (NYSE:BSX) Announces CFO Retirement And Strong Earnings Growth",
    "summary": "Boston Scientific (NYSE:BSX) recently announced a significant change to its leadership team with the planned retirement of CFO Dan Brennan, to be succeeded by Jon Monson. Alongside this transition, Boston Scientific released robust Q1 2025 earnings, showing increased sales and net income year-over-year, which aligns well with the broader market trend of positive reactions to recent earnings reports. The company's stock saw a 3.85% rise over the past week amidst a market environment where...",
    "url": "https://finnhub.io/api/news?id=796caada194d24a11327b1d17e1df9a5577e234c9e507fe34f5a81097044b2ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745518517,
      "headline": "Boston Scientific (NYSE:BSX) Announces CFO Retirement And Strong Earnings Growth",
      "id": 134067647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (NYSE:BSX) recently announced a significant change to its leadership team with the planned retirement of CFO Dan Brennan, to be succeeded by Jon Monson. Alongside this transition, Boston Scientific released robust Q1 2025 earnings, showing increased sales and net income year-over-year, which aligns well with the broader market trend of positive reactions to recent earnings reports. The company's stock saw a 3.85% rise over the past week amidst a market environment where...",
      "url": "https://finnhub.io/api/news?id=796caada194d24a11327b1d17e1df9a5577e234c9e507fe34f5a81097044b2ad"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=2769ea2726a236e3aff0ed895f644b59a45158217b1308851fa3e91f508e56cd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745512500,
      "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "id": 134073527,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=2769ea2726a236e3aff0ed895f644b59a45158217b1308851fa3e91f508e56cd"
    }
  },
  {
    "ts": null,
    "headline": "EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes",
    "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
    "url": "https://finnhub.io/api/news?id=8c4bdb9db29c78d4a11052a2b2b96e252e44d200bcf426dfa45700c7ba880a35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745509140,
      "headline": "EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes",
      "id": 134067483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "url": "https://finnhub.io/api/news?id=8c4bdb9db29c78d4a11052a2b2b96e252e44d200bcf426dfa45700c7ba880a35"
    }
  },
  {
    "ts": null,
    "headline": "Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=6830b1c6e9fdbc210210bb218122d207ed52cbb29c0024497c828c540e84dc01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745502307,
      "headline": "Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term",
      "id": 134067649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=6830b1c6e9fdbc210210bb218122d207ed52cbb29c0024497c828c540e84dc01"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific First Quarter 2025 Earnings: Beats Expectations",
    "summary": "Boston Scientific ( NYSE:BSX ) First Quarter 2025 Results Key Financial Results Revenue: US$4.66b (up 21% from 1Q...",
    "url": "https://finnhub.io/api/news?id=e1fcaecdbd5e8eeec4afb9a9266ec9267a80b8938dc789d466b979bcfcc9065c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745498023,
      "headline": "Boston Scientific First Quarter 2025 Earnings: Beats Expectations",
      "id": 134059507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific ( NYSE:BSX ) First Quarter 2025 Results Key Financial Results Revenue: US$4.66b (up 21% from 1Q...",
      "url": "https://finnhub.io/api/news?id=e1fcaecdbd5e8eeec4afb9a9266ec9267a80b8938dc789d466b979bcfcc9065c"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp (BSX) Q1 2025 Earnings Call Highlights: Strong Growth and Upgraded ...",
    "summary": "Boston Scientific Corp (BSX) reports robust sales growth and raises full-year guidance, despite facing tariff impacts and supply chain issues.",
    "url": "https://finnhub.io/api/news?id=cada3f194d42e3a8c6325cebf8e9eef107143081a0ecc03f7c36b9df4805fca3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745478140,
      "headline": "Boston Scientific Corp (BSX) Q1 2025 Earnings Call Highlights: Strong Growth and Upgraded ...",
      "id": 134059508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corp (BSX) reports robust sales growth and raises full-year guidance, despite facing tariff impacts and supply chain issues.",
      "url": "https://finnhub.io/api/news?id=cada3f194d42e3a8c6325cebf8e9eef107143081a0ecc03f7c36b9df4805fca3"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 Boston Scientific Corp Earnings Call",
    "summary": "Q1 2025 Boston Scientific Corp Earnings Call",
    "url": "https://finnhub.io/api/news?id=ffdb606676280a99fbd82f58ab163ec71849549960f94585156fcfc55c7c6622",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745463642,
      "headline": "Q1 2025 Boston Scientific Corp Earnings Call",
      "id": 134059509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Q1 2025 Boston Scientific Corp Earnings Call",
      "url": "https://finnhub.io/api/news?id=ffdb606676280a99fbd82f58ab163ec71849549960f94585156fcfc55c7c6622"
    }
  }
]